Table 8.
Russia.
| (A) | 03/24–06/07/2020 | |||
|---|---|---|---|---|
| Position | Location | Mutation | Count | Incidence |
| 241nt | 5´UTR | CG → TG | 215/226 | prevalent |
| noneffective | ||||
| 3,037nt | nsp3 | CT → TT | 224/226 | prevalent |
| noneffective | ||||
| 3,140nt | CC → TC | 13/226 | unique | |
| CCT (Proline) → AATCTT (Asparagine Leucine) | ||||
| 14,408nt | RNA‐dependent RNA polymerase | CT → TT | 225/226 | prevalent |
| CCT (Proline) → CTT (Leucine) | ||||
| 20,268nt | endoRNAse | AG → GG | 32/226 | ES,FR,US, |
| noneffective | ZA | |||
| 23,403nt | Spike glycoprotein | AT → GT | 226/226 | prevalent |
| GAT (Aspartic Acid) → GGT (Glycine) | ||||
| 25,563nt | ORF3a protein | GA → TA | 10/226 | prevalent |
| CAGAGC (Glutamine Serine) → CATAGC (Histidine Serine) | ||||
| 26,750nt | Membrane glycoprotein | CA → TA | 45/226 | unique |
| noneffective | ||||
| 27,415nt | ORF6 protein | GC → TC | 10/226 | unique |
| GCA (Alanine) → TCA (Serine) | ||||
| 28,881nt | Nucleocapsid phosphoprotein | GGG → AAC | 172/226 | prevalent |
| AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine) | ||||
| (B) | 01/19/2020–01/20/2021 | |||
|---|---|---|---|---|
| Position | Location | Mutation | Total Count | Percentage |
| 30nt | 3´UTR | A → G | 57 | 4.75 |
| 241nt | C → T | 1,167 | 97.33 | |
| 1,059nt | nsp2 | C → T | 31 | 2.59 |
| 3,037nt | nsp3 | C → T | 1,188 | 99.08 |
| 3,177nt | C → T | 28 | 2.34 | |
| 3,373nt | C → A | 43 | 3.59 | |
| 6,874nt | T → G | 72 | 6.01 | |
| 6,883nt | C → T | 38 | 3.17 | |
| 8,887nt | nsp4 | A → G | 108 | 9.01 |
| 11,029nt | nsp6 | G → A | 41 | 3.42 |
| 11,083nt | G → T | 32 | 2.67 | |
| 12,316nt | nsp8 | A → G | 28 | 2.34 |
| 12,886nt | nsp9 | A → G | 39 | 3.25 |
| 13,599nt | RNA‐dependent RNA polymerase | T → C | 63 | 5.25 |
| 14,408nt | C → T | 1,180 | 98.42 | |
| 15,540nt | C → T | 29 | 2.42 | |
| 19,839nt | endoRNAse | T → C | 105 | 8.76 |
| 20,268nt | A → G | 47 | 3.92 | |
| 21,724nt | Spike glycoprotein | G → A | 38 | 3.17 |
| 21,772nt | C → T | 41 | 3.42 | |
| 22,020nt | T → C | 73 | 6.09 | |
| 23,403nt | A → G | 1,195 | 99.67 | |
| 25,563nt | ORF3a | G → T | 43 | 3.59 |
| 26,750nt | Membrane glycoprotein | C → T | 53 | 4.42 |
| 27,415nt | ORF7a | G → T | 34 | 2.84 |
| 28,253nt | ORF8 | C → T | 32 | 2.67 |
| 28,881nt | Nucleocapsid phosphoprotein | G → A | 1,079 | 89.99 |
| 28,882nt | G → A | 1,079 | 89.99 | |
| 28,883nt | G → C | 1,075 | 89.66 | |
| 28,905nt | C → T | 62 | 5.17 | |
| 28,975nt | G → T | 24 | 2 | |
| 29,518nt | ORF10 | C → T | 49 | 4.09 |
The general design of these Tables follows the outline described in detail in the legend to Table 5 (United States). The number of sequences investigated for SARS‐CoV‐2 mutations is detailed in Tables for individual countries.